SCHEMBL25950360

SCHEMBL25950360

Cn1c(=O)[nH]c2ncc(C(C)(C)C)nc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA2B P29275 3/20 0.41
LMNA P02545 2/20 0.41
ADORA2A P29274 2/20 0.41
MEN1 O00255 1/20 0.41
PABPC1 P11940 1/20 0.41
KMT2A Q03164 1/20 0.41
ALDH1A1 P00352 3/20 0.39
KDM4E B2RXH2 2/20 0.39
GAA P10253 2/20 0.39
GLA P06280 1/20 0.39
HPGD P15428 1/20 0.39
PDE2A O00408 2/20 0.39
PDE3B Q13370 2/20 0.39
PDE3A Q14432 2/20 0.39
CYP3A4 P08684 2/20 0.38
PMP22 Q01453 2/20 0.38
MAPT P10636 1/20 0.38
TSHR P16473 1/20 0.38
BLM P54132 1/20 0.38
MAPK1 P28482 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24995481 0.83 CYP1A2 (0.35) ADORA2BLMNAADORA2AALDH1A1KDM4E
SCHEMBL24995677 0.80 MTOR (0.55) ADORA2BCYP3A4CYP1A2MTOR
SCHEMBL17813483 0.78 LMNA (0.45) ADORA2BLMNAADORA2AMEN1PABPC1
SCHEMBL22836260 0.77 LMNA (0.44) ADORA2BLMNAADORA2AMEN1PABPC1
SCHEMBL28529536 0.73 CYP1A2 (0.63) ADORA2BLMNAADORA2AMEN1PABPC1
SCHEMBL26024589 0.71 LMNA (0.49) ADORA2BLMNAADORA2AMEN1PABPC1
SCHEMBL19286119 0.70 RPS6KA3 (0.38) MEN1KMT2AALDH1A1KDM4EGAA
SCHEMBL28512965 0.70 CYP1A2 (0.43) ADORA2BLMNAADORA2AMEN1PABPC1
SCHEMBL979460 0.70 LMNA (0.46) ADORA2BLMNAADORA2AMEN1PABPC1
SCHEMBL29795155 0.70 LMNA (0.46) ADORA2BLMNAADORA2AMEN1PABPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271939-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS IP2IPO INNOVATIONS LIMITED (GB) 2023-08-31 US disclosed
US-20230250082-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS IP2IPO INNOVATIONS LIMITED (GB) 2023-08-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230271939-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS EIF2AK4, GCN1, EIF5B ADORA2B 2349/4885LMNA 2905/4885ADORA2A 3336/4885
US-20230250082-A1 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS EIF2AK4, GCN1, EIF5B ADORA2B 2349/4885LMNA 2905/4885ADORA2A 3336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.